Shares of Apogee Therapeutics (NASDAQ:APGE) jumped 15% on Monday after the company reported positive 52-week results from Part A of its Phase 2 APEX study evaluating zumilokibart (APG777) in patients with moderate-to-severe atopic dermatitis.
The data showed that treatment responses were maintained through 52 weeks with both quarterly and twice-yearly dosing schedules. Among patients who responded by week 16, 75% maintained EASI-75 with dosing every three months, while 85% maintained the same response level with dosing every six months. In addition, 86% and 78% of week-16 responders sustained vIGA 0/1 scores under the three-month and six-month regimens, respectively.
Apogee said patients across the full study population initially assigned to zumilokibart experienced deeper improvements across multiple lesion and itch-related measures under both dosing schedules. The treatment was generally well tolerated, with a safety profile largely consistent with other therapies in the same class.
The maintenance phase of the study evaluated a 360 mg dose of zumilokibart administered at three-month and six-month intervals. The most frequently reported treatment-emergent adverse events included noninfective conjunctivitis, upper respiratory tract infection and nasopharyngitis.
The company expects to release 16-week induction data from Part B of the trial in the second quarter of 2026. Those results are expected to support the planned launch of Phase 3 studies for moderate-to-severe atopic dermatitis in the second half of 2026. Pending regulatory approval, Apogee anticipates a potential commercial launch of the therapy in 2029.
The new findings are scheduled to be presented in a late-breaking oral session at the 2026 American Academy of Dermatology Annual Meeting on March 28.
Zumilokibart is an anti-IL-13 antibody designed to reduce dosing frequency compared with existing treatments for atopic dermatitis, some of which can require up to 26 injections per year.